RICE BRAN ARABINOXYLAN COMPOUND: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Rice bran arabinoxylan compound is an extract of arabinoxylan from rice bran. It is used as a medicine.

Rice bran arabinoxylan compound is most commonly used for boosting the immune system. It is also used for cancer, reducing side effects of cancer treatment, chronic fatigue syndrome (CFS), hepatitis C, and other conditions, but there is no good scientific evidence to support these uses.

How does it work ?

Rice bran arabinoxylan compound might work by improving the body's natural immune system.

Uses & Effectiveness

Insufficient Evidence for

Chronic fatigue syndrome (CFS). Early research suggested that rice bran arabinoxylan compound might improve symptoms and immune function in people with CFS. But more recent evidence shows that rice bran arabinoxylan compound does not improve symptoms of CFS including fatigue. All of the studies to date have been small and/or low quality, so more high quality research is needed.
Swelling (inflammation) of the liver caused by the hepatitis C virus (hepatitis C). Early research suggests that taking rice bran arabinoxylan compound helps to clear hepatitis C virus from the bloodstream in people with a certain type of hepatitis C. It seems to work as well as pegylated interferon plus ribavirin.
HIV/AIDS. Early research shows that taking rice bran arabinoxylan does not improve most blood markers of HIV/AIDS.
Liver cancer. Early research shows that taking rice bran arabinoxylan compound in combination with standard therapy might help people with liver cancer live longer compared to standard therapy alone. It might also help prevent liver cancer from returning after treatment.
Quality of life. Early research shows that taking rice bran arabinoxylan 250 mg daily for 3 months may improve self-reported quality of life in older adults.
Boosting immune function.
Diabetes.
Preventing and treating cancer.
Other conditions.

More evidence is needed to rate the effectiveness of rice bran arabinoxylan compound for these uses.

Side Effects

When taken by mouth: Rice bran arabinoxylan compound is POSSIBLY SAFE when taken by mouth short-term. Rice bran arabinoxylan compound has been used safely in doses of 1 gram daily for 12 months or up to 6 grams daily for 2-3 months. There isn't enough reliable information to know whether rice bran arabinoxylan compound is safe to take for a longer period of time.

Special Precautions and Warnings

Pregnancy and breast-feeding: Not enough is known about the use of rice bran arabinoxylan compound during pregnancy and breast-feeding. Stay on the safe side and avoid use.

"Auto-immune diseases" such as multiple sclerosis (MS), lupus (systemic lupus erythematosus, SLE), rheumatoid arthritis (RA), or other conditions: Rice bran arabinoxylan compound might cause the immune system to become more active. This might increase the symptoms of auto-immune diseases. If you have one of these conditions, it's best to avoid using rice bran arabinoxylan compound.

Interactions

Moderate Interaction

Be cautious with this combination

Medications that decrease the immune system (Immunosuppressants) interacts with RICE BRAN ARABINOXYLAN COMPOUND
Rice bran arabinoxylan compound might increase the immune system. By increasing the immune system, rice bran arabinoxylan compound might decrease the effectiveness of medications that decrease the immune system.
Some medications that decrease the immune system include azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf), sirolimus (Rapamune), prednisone (Deltasone, Orasone), corticosteroids (glucocorticoids), and others.

Dosing

The appropriate dose of rice bran arabinoxylan compound depends on several factors such as the user's age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for rice bran arabinoxylan compound. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.

View References

REFERENCES:

Michelini S, Fiorentino A, Cardone M. Melilotus, rutin and bromelain in primary and secondary lymphedema. Lymphology 2019;52(4):177-86. View abstract.

Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Int Med 1998;158:2200-11.. View abstract.

Moser M, Ranacher G, Wilmot TJ, et al. A double-blind clinical trial of hydroxyethylrutosides in Meniere's disease. J Laryngol Otol 1984;98(3):265-272. View abstract.

Neumann HA, van den Broek MJ. A comparative clinical trial of graduated compression stockings and O-(beta-hydroxyethyl)-rutosides (HR) in the treatment of patients with chronic venous insufficiency. Z Lymphol 1995;19(1):8-11. View abstract.

Nocker W, Diebschlag W, Lehmacher W. [A 3-month, randomized double-blind dose-response study with 0-(beta-hydroxyethyl)-rutoside oral solutions]. Vasa 1989;18(3):235-238. View abstract.

Oliveira VM, Carraro E, Auler ME, Khalil NM. Quercetin and rutin as potential agents antifungal against Cryptococcus spp. Braz J Biol 2016;76(4):1029-34. View abstract.

Pedersen FM, Hamberg O, Sorensen MD, et al. [Effect of 0-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs]. Ugeskr Laeger 1992;154(38):2561-2563. View abstract.

Peres DA, de Oliveira CA, da Costa MS, et al. Rutin increases critical wavelength of systems containing a single UV filter and with good skin compatibility. Skin Res Technol. 2016;22(3):325-33. View abstract.

Perez Guerrero C, Martin MJ, Marhuenda E. Prevention by rutin of gastric lesions induced by ethanol in rats: role of endogenous prostaglandins. Gen Pharmacol 1994;25:575-80. View abstract.

Petruzzellis V, Troccoli T, Candiani C, et al. Oxerutins (Venoruton): efficacy in chronic venous insufficiency--a double-blind, randomized, controlled study. Angiology 2002;53(3):257-263. View abstract.

Piller NB, Morgan RG, Casley-Smith JR. A double-blind, cross-over trial of O-(beta-hydroxyethyl)-rutosides (benzo-pyrones) in the treatment of lymphoedema of the arms and legs. Br J Plast Surg 1988;41(1):20-27. View abstract.

Pischnamazzadeh M. [Prevention of radiation-induced skin reactions in breast cancer]. Strahlentherapie 1983;159(1):9-12. View abstract.

Poynard T, Valterio C. Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency. Vasa 1994;23(3):244-250. View abstract.

Prerovsky I, Roztocil K, Hlavova A, et al. The effect of hydroxyethylrutosides after acute and chronic oral administration in patients with venous diseases. A double-blind study. Angiologica 1972;9(3-6):408-414. View abstract.

Pronk LC, van Putten WL, van B, V, et al. The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study. Cancer Chemother Pharmacol 1999;43(2):173-177. View abstract.

Bang MH, Van Riep T, Thinh NT, et al. Arabinoxylan rice bran (MGN-3) enhances the effects of interventional therapies for the treatment of hepatocellular carcinoma: a three-year randomized clinical trial. Anticancer Res. 2010;30(12):5145-51. View abstract.

Cholujova D, Jakubikova J, Czako B, et al. MGN-3 arabinoxylan rice bran modulates innate immunity in multiple myeloma patients. Cancer Immunol Immunother. 2013;62(3):437-45. View abstract.

Elsaid AF, Fahmi RM, Shaheen M, Ghoneum M. The enhancing effects of Biobran/MGN-3, an arabinoxylan rice bran, on healthy old adults' health-related quality of life: a randomized, double-blind, placebo-controlled clinical trial. Qual Life Res. 2020 Feb;29(2):357-367. View abstract.

FDA Talk Paper. FDA takes action against firm marketing unapproved drugs. 1999. Available at: www.fda.gov/bbs/topics/ANSWERS/ANS00988.html

Ghoneum M, Agrawal S. Activation of human monocyte-derived dendritic cells in vitro by the biological response modifier arabinoxylan rice bran (MGN-3/Biobran). Int J Immunopathol Pharmacol. 2011;24(4):941-8. View abstract.

Ghoneum M, Agrawal S. Mgn-3/biobran enhances generation of cytotoxic CD8+ T cells via upregulation of dec-205 expression on dendritic cells. Int J Immunopathol Pharmacol. 2014;27(4):523-30. View abstract.

Ghoneum M, Jewett A. Production of tumor necrosis factor-alpha and interferon-gamma from human peripheral blood lymphocytes by MGN-3, a modified arabinoxylan from rice bran, and its synergy with interleukin-2 in vitro. Cancer Detect Prev. 2000;24(4):314-24. View abstract.

Ghoneum M, Jewett A. Synergistic effect of modified arabinoxylane (MGN-3) and low dose of recombinant IL-2 on human NK cell activity and TNF-a production. American Academy of Anti-Aging Medicine, Education Conference 1998.

Ghoneum M, Matsuura M. Augmentation of macrophage phagocytosis by modified arabinoxylan rice bran (MGN-3/biobran). Int J Immunopathol Pharmacol. 2004;17(3):283-92. View abstract.

Ghoneum M, Namatalia G, Kim C. Effect of MGN-3 on human natural killer cell activity and interferon-y synthesis in vitro. FASEB 1996;10:26-32.

Ghoneum M, Namatalla G. NK immunomodulatory function in 27 cancer patients by MGN-3, a modified arabinoxylane from rice bran. 87th Annual Meeting of the American Association for Cancer Research 1996.

Ghoneum M. Anti-HIV activity in vitro of MGN-3, an activated arabinoxylane from rice bran. Biochem Biophys Res Commun 1998;243:25-9. View abstract.

Ghoneum M. Enhancement of human natural killer cell activity by modified arabinoxylane from rice bran (MGN-3). Int J Immunotherapy 1998;14:89-99.

Ghoneum M. Immunomodulatory and anti-cancer properties of MGN-3, a modified xylose from rice bran, in 5 patients with breast cancer [abstract]. American Association for Cancer Research Special Conference. November 5-8, 1995.

Lewis JE, Atlas Bsn SE, Abbas MH, et al. The novel effects of a hydrolyzed polysaccharide dietary supplement on immune, hepatic, and renal function in adults with HIV in a randomized, double-blind, placebo-control trial. J Diet Suppl. 2020;17(4):429-441. View abstract.

Lewis JE, Atlas SE, Abbas MH, et al. Cardiovascular, endothelial function, and immune markers in response to treatment with a polysaccharide in HIV + adults in a randomized, double-blind placebo-controlled trial. J Clin Transl Res. 2020 Apr 13;5(3):140-147. View abstract.

McDermott C, Richards SC, Thomas PW, Montgomery J, Lewith G. A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome. QJM. 2006;99(7):461-8. View abstract.

Ooi SL, McMullen D, Golombick T, Nut D, Pak SC. Evidence-based review of BioBran/MGN-3 arabinoxylan compound as a complementary therapy for conventional cancer treatment. Integr Cancer Ther. 2018;17(2):165-178. View abstract.

Salama H, Medhat E, Shaheen M, Zekri AN, Darwish T, Ghoneum M. Arabinoxylan rice bran (Biobran) suppresses the viremia level in patients with chronic HCV infection: A randomized trial. Int J Immunopathol Pharmacol. 2016;29(4):647-653. View abstract.

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2024 by Therapeutic Research Center, LLC. All Rights Reserved.